OBJECTIVES: To determine the neuropathological load in the living brain of nondemented adults with Down syndrome using positron emission tomography with 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) and to assess the influence of age and cognitive and behavioral functioning. For reference, [(18)F]FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants. DESIGN: Cross-sectional clinical study. PARTICIPANTS: Volunteer sample of 19 persons with Down syndrome without dementia (mean age, 36.7 years), 10 patients with Alzheimer disease (mean age, 66.5 years), and 10 controls (mean age, 43.8 years). MAIN OUTCOME MEASURES: Binding of [(18)F]FDDNP in brain regions of interest, including the parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus, and the average of all regions (global binding). RESULTS: The [(18)F]FDDNP binding values were higher in all brain regions in the Down syndrome group than in controls. Compared with the Alzheimer disease group, the Down syndrome group had higher [(18)F]FDDNP binding values in the parietal and frontal regions, whereas binding levels in other regions were comparable. Within the Down syndrome group, age correlated with [(18)F]FDDNP binding values in all regions except the posterior cingulate, and several measures of behavioral dysfunction showed positive correlations with global, frontal, parietal, and posterior cingulate [(18)F]FDDNP binding. CONCLUSIONS: Consistent with neuropathological findings from postmortem studies, [(18)F]FDDNP positron emission tomography shows high binding levels in Down syndrome comparable to Alzheimer disease and greater levels than in members of a control group. The positive associations between [(18)F]FDDNP binding levels and age as well as behavioral dysfunction in Down syndrome are consistent with the age-related progression of Alzheimer-type neuropathological findings in this population.
OBJECTIVES: To determine the neuropathological load in the living brain of nondemented adults with Down syndrome using positron emission tomography with 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) and to assess the influence of age and cognitive and behavioral functioning. For reference, [(18)F]FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants. DESIGN: Cross-sectional clinical study. PARTICIPANTS: Volunteer sample of 19 persons with Down syndrome without dementia (mean age, 36.7 years), 10 patients with Alzheimer disease (mean age, 66.5 years), and 10 controls (mean age, 43.8 years). MAIN OUTCOME MEASURES: Binding of [(18)F]FDDNP in brain regions of interest, including the parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus, and the average of all regions (global binding). RESULTS: The [(18)F]FDDNP binding values were higher in all brain regions in the Down syndrome group than in controls. Compared with the Alzheimer disease group, the Down syndrome group had higher [(18)F]FDDNP binding values in the parietal and frontal regions, whereas binding levels in other regions were comparable. Within the Down syndrome group, age correlated with [(18)F]FDDNP binding values in all regions except the posterior cingulate, and several measures of behavioral dysfunction showed positive correlations with global, frontal, parietal, and posterior cingulate [(18)F]FDDNP binding. CONCLUSIONS: Consistent with neuropathological findings from postmortem studies, [(18)F]FDDNP positron emission tomography shows high binding levels in Down syndrome comparable to Alzheimer disease and greater levels than in members of a control group. The positive associations between [(18)F]FDDNP binding levels and age as well as behavioral dysfunction in Down syndrome are consistent with the age-related progression of Alzheimer-type neuropathological findings in this population.
Authors: Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Kris A Johnson; David S Knopman; Bradley F Boeve; Gregory A Jicha; Robert J Ivnik; Glenn E Smith; Eric G Tangalos; Heiko Braak; Emre Kokmen Journal: Arch Neurol Date: 2006-05
Authors: Linda Nelson; Julene K Johnson; Morris Freedman; Ira Lott; Jantje Groot; Marisa Chang; Norton William Milgram; Elizabeth Head Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2005-03 Impact factor: 5.067
Authors: Anand Kumar; Vladimir Kepe; Jorge R Barrio; Prabha Siddarth; Vicki Manoukian; Virginia Elderkin-Thompson; Gary W Small Journal: Arch Gen Psychiatry Date: 2011-11
Authors: Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian Journal: Neurobiol Aging Date: 2017-06-02 Impact factor: 4.673
Authors: Marwan N Sabbagh; Kewei Chen; Joseph Rogers; Adam S Fleisher; Carolyn Liebsack; Dan Bandy; Christine Belden; Hillary Protas; Pradeep Thiyyagura; Xiaofen Liu; Auttawut Roontiva; Ji Luo; Sandra Jacobson; Michael Malek-Ahmadi; Jessica Powell; Eric M Reiman Journal: Alzheimers Dement Date: 2015-04-04 Impact factor: 21.566
Authors: Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Patrick J Lao; Ben L Handen; Tobey J Betthauser; Iulia Mihaila; Sigan L Hartley; Annie D Cohen; Dana L Tudorascu; Peter D Bulova; Brian J Lopresti; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Todd E Barnhart; Charles K Stone; Julie C Price; Darlynne A Devenny; Sterling C Johnson; William E Klunk; Bradley T Christian Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Julie C Lauterborn; Conor D Cox; See Wing Chan; Peter W Vanderklish; Gary Lynch; Christine M Gall Journal: Brain Pathol Date: 2019-09-08 Impact factor: 6.508
Authors: David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head Journal: Neurobiol Aging Date: 2014-02-04 Impact factor: 4.673
Authors: Sigan L Hartley; Benjamin L Handen; Darlynne A Devenny; Regina Hardison; Iulia Mihaila; Julie C Price; Annie D Cohen; William E Klunk; Marsha R Mailick; Sterling C Johnson; Bradley T Christian Journal: Brain Date: 2014-07-02 Impact factor: 13.501